Facebook
TwitterData on drug overdose death rates, by drug type and selected population characteristics. Please refer to the PDF or Excel version of this table in the HUS 2019 Data Finder (https://www.cdc.gov/nchs/hus/contents2019.htm) for critical information about measures, definitions, and changes over time. SOURCE: NCHS, National Vital Statistics System, numerator data from annual public-use Mortality Files; denominator data from U.S. Census Bureau national population estimates; and Murphy SL, Xu JQ, Kochanek KD, Arias E, Tejada-Vera B. Deaths: Final data for 2018. National Vital Statistics Reports; vol 69 no 13. Hyattsville, MD: National Center for Health Statistics.2021. Available from: https://www.cdc.gov/nchs/products/nvsr.htm. For more information on the National Vital Statistics System, see the corresponding Appendix entry at https://www.cdc.gov/nchs/data/hus/hus19-appendix-508.pdf.
Facebook
Twitterhttps://creativecommons.org/publicdomain/zero/1.0/https://creativecommons.org/publicdomain/zero/1.0/
Over 93,000 people will die from drug overdoses in the United States in 2020, according to escalating death rates in recent years. Fentanyl and other synthetic opioids are a significant factor in the rise. The misuse of stimulants, benzodiazepines, and narcotic prescription drugs also contributes. A multimodal strategy is needed to address the problem, including better prescription drug monitoring schemes, more access to addiction treatment, and harm reduction tactics.
In recent years, the number of drug overdose deaths in the United States has become a significant public health concern. The misuse of prescription medications, the usage of synthetic opioids, and the lack of access to addiction treatment are a few of the causes contributing to the surge in drug overdose deaths. The problem emphasizes the requirement for successful treatments and preventative plans, as well as the necessity to deal with the social determinants of health that influence substance misuse.
Here are some drug prevention precautions that are important to keep in mind:
Facebook
TwitterThis data presents provisional counts for drug overdose deaths based on a current flow of mortality data in the National Vital Statistics System. Counts for the most recent final annual data are provided for comparison. National provisional counts include deaths occurring within the 50 states and the District of Columbia as of the date specified and may not include all deaths that occurred during a given time period. Provisional counts are often incomplete and causes of death may be pending investigation resulting in an underestimate relative to final counts. To address this, methods were developed to adjust provisional counts for reporting delays by generating a set of predicted provisional counts. Several data quality metrics, including the percent completeness in overall death reporting, percentage of deaths with cause of death pending further investigation, and the percentage of drug overdose deaths with specific drugs or drug classes reported are included to aid in interpretation of provisional data as these measures are related to the accuracy of provisional counts. Reporting of the specific drugs and drug classes involved in drug overdose deaths varies by jurisdiction, and comparisons of death rates involving specific drugs across selected jurisdictions should not be made. Provisional data presented will be updated on a monthly basis as additional records are received. For more information please visit: https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm
Facebook
Twitterhttps://creativecommons.org/publicdomain/zero/1.0/https://creativecommons.org/publicdomain/zero/1.0/
https://www.googleapis.com/download/storage/v1/b/kaggle-user-content/o/inbox%2F16731800%2F8a1e63df085793d18e2d1fa2109ebd44%2Fgrap%20video%201.gif?generation=1708634385396138&alt=media" alt="">
https://www.googleapis.com/download/storage/v1/b/kaggle-user-content/o/inbox%2F16731800%2F296225796c579724b56cb1d746475d93%2FToday%20(1).gif?generation=1708634392024756&alt=media" alt="">
Annual number of deaths in the United States from drug overdose per 100,000 people. Overdoses can result from intentional excessive use of a substance, but can also result from 'poisoning' where substances have been altered or mixed, such that the user is unaware of the drug's potency.
The data of this indicator is based on the following sources: US Centers for Disease Control and Prevention WONDER Data published by US Centers for Disease Control and Prevention WONDER
Retrieved from https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates How we process data at Our World in Data: All data and visualizations on Our World in Data rely on data sourced from one or several original data providers. Preparing this original data involves several processing steps. Depending on the data, this can include standardizing country names and world region definitions, converting units, calculating derived indicators such as per capita measures, as well as adding or adapting metadata such as the name or the description given to an indicator.
At the link below you can find a detailed description of the structure of our data pipeline, including links to all the code used to prepare data across Our World in Data.
Read about our data pipeline How to cite this data: In-line citation If you have limited space (e.g. in data visualizations), you can use this abbreviated in-line citation:
Any opioids Deaths per 100,000 people attributed to any opioids.
Source US Centers for Disease Control and Prevention WONDER â processed by Our World in Data Unit deaths per 100,000
Facebook
TwitterOpen Government Licence 3.0http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/
License information was derived automatically
Annual number of deaths registered related to drug poisoning in England and Wales by sex, region and whether selected substances were mentioned anywhere on the death certificate, with or without other drugs or alcohol, and involvement in suicides.
Facebook
TwitterBy Health [source]
This dataset contains information on the alarming rate of opioid overdose deaths in the United States. From 2000 to 2014, the rate of drug overdoses rose dramatically, increasing by 137%, and even more so for overdoses involving opioids - with an increase of 200%. This data was compiled by the Centers for Disease Control and Prevention's National Center for Health Statistics and includes year-by-year records of opioid death rates and population figures.
Opioids are highly addictive stimulants that act on opioid receptors to produce powerful pain relief but can have devastating physical, emotional, and social effects if misused. Commonly prescribed medications such as Oxycodone and Hydrocodone are opioids while Heroin is an illegal form of these substances. This dataset also includes information on the number of prescriptions dispensed by US retailers in that same year â a further indication of how the opioid crisis is affecting Americans both medically and directly.
The human cost has been high: Weâre facing an epidemic with no easy way out involving grieving families turning to organ donation systems in hopes to help others from this tragedy; small-town cops learning first-hand how addiction ravages their communities; kids struggling at home with passed out parents who may not wake up from their high; waves of people overdosing from new drugs with unknown side effects slipping through our health care system; rising concerns about what appears once classified illnesses such as HIV becoming part of this larger puzzle.
These datasets can provide valuable insights into understanding how best to address this horrific trend, saving countless lives in its wake â help us make a difference today!
For more datasets, click here.
- đš Your notebook can be here! đš!
This dataset includes information on opioid overdose deaths in the United States from 1999-2014. It includes death rates, population figures, and opioid prescriptions dispensed by US retailers. This data is valuable for understanding the prevalence of opioid overdose deaths in different parts of the US and for identifying trends over time.
The columns include: State, Year, Deaths, Population, Crude Rate and Prescriptions Dispensed by US Retailers in that year (millions). By examining this dataset you can compare a state's raw number of deaths as well as its death rate per 100,000 people to gain a better perspective on how severe an issue this is at state level. Additionally you can examine how many prescriptions are being dispensed each year to understand if there is cause for concern with regard to potential overprescribing.
Finally you can use this data to analyze changes or identify correlations between various factors such as population size, number of deaths and prescription numbers across states or years. This will enable you to gain deeper insights into the causes of opioid overdoses and form more informed opinions about what should be done next in order combat this issue effectively
- Geographic Mapping: Generating visualizations 'heatmaps' to show the regional prevalence of both opioid overdose deaths and opioid prescriptions dispensed in order to compare with other regional population and health data to identify potential areas of need or at-risk groups.
- Resource Allocation & Program Development: Using the population and death rate information, city/state governments can better determine where resources need to be allocated for prevention programs, treatment programs, drug education outreach, harm reduction initiatives etc.
- Predictive Modeling/Analysis: Leveraging this dataset along with external datasets such as US census information, arrest/interdiction data, accessibility/availability variables etc., could potentially be used to create predictive models which can forecast areas in need of increased services or measures outside traditional healthcare approaches such as law enforcement interdiction efforts
If you use this dataset in your research, please credit the original authors. Data Source
Unknown License - Please check the dataset description for more information.
File: Multiple Cause of Death, 1999-2014.csv | Column name | Description | |:---------------|:--------------------------------------------------------------------------------------...
Facebook
TwitterOpen Government Licence 3.0http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/
License information was derived automatically
Deaths related to drug poisoning in England and Wales by cause of death, sex, age, substances involved in the death, geography and registration delay.
Facebook
Twitterhttp://www.gnu.org/licenses/old-licenses/gpl-2.0.en.htmlhttp://www.gnu.org/licenses/old-licenses/gpl-2.0.en.html
All opioids are chemically related and interact with opioid receptors on nerve cells in the body and brain. Opioid pain relievers can be misused (taken in a different way or in a larger quantity than prescribed, or taken without a doctorâs prescription). Regular use - even as prescribed by a doctor - can lead to dependence and, when misused, opioid pain relievers can lead to addiction, overdose incidents, and deaths. The National Institute on Drug Abuse collects and analyzes data about deaths from opioid abuse. This data set reports on data from 1999-2019.
| Key | List of... | Comment | Example Value |
|---|---|---|---|
| Year | Integer | The year for which the data is reported (1999-2019) | 1999 |
| Number.All | Integer | Total number of overdose deaths from all drugs | 16849 |
| Number.Opioid.Any | Integer | Total number of overdose deaths due to any Opioid drug | 8050 |
| Number.Opioid.Prescription | Integer | Total number of overdose deaths due to a prescription Opioid drug | 3442 |
| Number.Opioid.Synthetic | Integer | Total number of overdose deaths due to a synthetic Opioid drug (e.g. fentanyl) | 730 |
| Number.Opioid.Heroin | Integer | Total number of overdose deaths due to heroin | 1960 |
| Number.Opioid.Cocaine | Integer | Total number of overdose deaths due to cocaine | 3822 |
| Rate.All.Total | Float | The rate of overdose deaths due to all drugs per 100,000 people | 6.1 |
| Rate.All.Sex.Female | Float | The rate of overdose deaths among women due to all drugs per 100,000 people | 3.9 |
| Rate.All.Sex.Male | Float | The rate of overdose deaths among men due to all drugs per 100,000 people | 8.2 |
| Rate.All.Race.White | Float | The rate of overdose deaths among White non-Hispanic persons due to all drugs per 100,000 people | 6.2 |
| Rate.All.Race.Black | Float | The rate of overdose deaths among Black non-Hispanic persons from all drugs per 100,000 people | 7.5 |
| Rate.All.Race.Asian or Pacific Islander | Float | The rate of overdose deaths among Asian or Pacific Islander non-Hispanic persons from all drugs per 100,000 people | 1.2 |
| Rate.All.Race.Hispanic | Float | The rate of overdose deaths among Hispanic persons due to all drugs per 100,000 people | 5.4 |
| Rate.All.Race.American Indian or Alaska Native | Float | The rate of overdose deaths among American Indian or Alaska Native non-Hispanic persons due to all drugs per 100,000 people | 6.0 |
| Rate.Opioid.Any.Total | Float | The rate of overdose deaths due to any Opioid drug per 100,000 people | 2.9 |
| Rate.Opioid.Any.Sex.Female | Float | The rate of overdose deaths among women due to any Opioid drug per 100,000 people | 1.4 |
| Rate.Opioid.Any.Sex.Male | Float | The rate of overdose deaths among men due to any Opioid drug per 100,000 people | 4.3 |
| Rate.Opioid.Any.Race.White | Float | The rate of overdose deaths among White non-Hispanic persons due to any Opioid drug per 100,000 people | 2.8 |
| Rate.Opioid.Any.Race.Black | Float | The rate of overdose deaths among Asian or Pacific Islander non-Hispanic persons due to any Opioid drug per 100,000 people | 3.5 |
| Rate.Opioid.Any.Race.Asian or Pacific Islander | Float | The rate of overdose deaths among Black non-Hispanic persons due to any Opioid drug per 100,001 people | 0.3 |
| Rate.Opioid.Any.Race.Hispanic | Float | The rate of overdose deaths among Hispanic persons due to any Opi... |
Facebook
TwitterTo: State, territorial, tribal, and local policymakers and administrators of agencies and programs focused on child, youth, and family health and well-being Dear Colleagues, Thank you for your work to support children, youth, and families. Populations served by Administration for Children and Families (ACF)-funded programs â including victims of trafficking or violence, those who are unhoused, and young people and families involved in the child welfare system â are often at particularly high risk for substance use and overdose. A variety of efforts are underway at the federal, state, and local levels to reduce overdose deaths. These efforts focus on stopping drugs from entering communities, providing life-saving resources, and preventing drug use before it starts. Initiatives across the country are already saving lives: the overdose death rate has declined over the past year but remains too high at 32.6 per 100,000 individuals. Fentanyl, a powerful synthetic opioid, raises the risk of overdose deaths because even a tiny amount can be deadly. Young people are particularly at risk for fentanyl exposure, driven in part by widespread availability of counterfeit pills containing fentanyl that are marketed to youth through social media. While overdose deaths among teens have recently begun to decline, there were 6,696 deaths among adolescents and young adults in 2022 (the latest year with data available)[1], making unintentional drug overdose the second leading cause of death for youth ages 15â19 and the first leading cause of death among young adults ages 20-24.[2] Often these deaths happen with others nearby and can be prevented when opioid overdose reversal medications, like naloxone, are administered in time. CDCâs State Unintentional Drug Overdose Reporting System dashboard shows that in all 30 jurisdictions with available data, 64.7% of drug overdose deaths had at least one potential opportunity for intervention.[3] Naloxone rapidly reverses an overdose and should be given to any person who shows signs of an opioid overdose or when an overdose is suspected. It can be given as a nasal spray. Studies show that naloxone administration reduces death rates and does not cause harm if used on a person who is not overdosing on opioids. States have different policies and regulations regarding naloxone distribution and administration. Forty-nine states and the District of Columbia have Good Samaritan laws protecting bystanders who aid at the scene of an overdose.[4] ACF grant recipients and partners can play a critical role in reducing overdose deaths by taking the following actions: Stop Overdose Now (U.S. Centers for Disease Control and Prevention) Integrating Harm Reduction Strategies into Services and Supports for Young Adults Experiencing Homelessness (PDF) (ACF) Thank you for your dedication and partnership. If you have any questions, please contact your local public health department or state behavioral health agency. Together, we can meaningfully reduce overdose deaths in every community. /s/ Meg Sullivan Principal Deputy Assistant Secretary [1] Products - Data Briefs - Number 491 - March 2024 [2] WISQARS Leading Causes of Death Visualization Tool [3] SUDORS Dashboard: Fatal Drug Overdose Data | Overdose Prevention | CDC [4] Based on 2024 report from the Legislative Analysis and Public Policy Association (PDF). Note that the state of Kansas adopted protections as well following the publication of this report. Metadata-only record linking to the original dataset. Open original dataset below.
Facebook
Twitterhttp://data.europa.eu/eli/dec/2011/833/ojhttp://data.europa.eu/eli/dec/2011/833/oj
Drug-related mortality is a complex phenomenon, which accounts for a considerable percentage of deaths among young people in many European countries. The EMCDDA, in collaboration with national experts, has defined an epidemiological indicator with two components at present: deaths directly caused by illegal drugs (drug-induced deaths) and mortality rates among problem drug users. These two components can fulfil several public health objectives, notably as an indicator of the overall health impact of drug use and the components of this impact, identify particularly risky patterns of use, and potentially identify new risks.
There are around 50 statistical tables in this dataset. Each data table may be viewed as an HTML table or downloaded in spreadsheet (Excel format).
Facebook
TwitterCC0 1.0 Universal Public Domain Dedicationhttps://creativecommons.org/publicdomain/zero/1.0/
License information was derived automatically
This dataset includes a subset of data collected through the Johns Hopkins University social network-based intervention study CHAMPS CONNECT conducted in Baltimore, Maryland. A total of 111 people who inject drugs (PWID) were recruited from an infectious disease clinic and community-based sites in Baltimore between 1/25/2018 and 1/4/2019. Index members were 18 years of age or older, English speaking, hepatitis C virus (HCV) antibody positive, and reported injecting drugs with another during the past year. Indexes were asked to recruit their injection drug network members for HCV testing and linkage to care. The primary objective of the secondary study was to analyze data from indexes and network participant members to assess psychological factors that may be significantly associated with self-reported number of lifetime drug overdoses. Variables in the dataset include demographics, employment, substance use history and treatment, mental health diagnoses and treatment, overdose, injection drug use, and questions from the Center of Epidemiologic Studies Depression Scale.
Facebook
TwitterEMSIndicators:The number of individual patients administered naloxone by EMSThe number of naloxone administrations by EMSThe rate of EMS calls involving naloxone administrations per 10,000 residentsData Source:The Vermont Statewide Incident Reporting Network (SIREN) is a comprehensive electronic prehospital patient care data collection, analysis, and reporting system. EMS reporting serves several important functions, including legal documentation, quality improvement initiatives, billing, and evaluation of individual and agency performance measures.Law Enforcement Indicators:The Number of law enforcement responses to accidental opioid-related non-fatal overdosesData Source:The Drug Monitoring Initiative (DMI) was established by the Vermont Intelligence Center (VIC) in an effort to combat the opioid epidemic in Vermont. It serves as a repository of drug data for Vermont and manages overdose and seizure databases. Notes:Overdose data provided in this dashboard are derived from multiple sources and should be considered preliminary and therefore subject to change. Overdoses included are those that Vermont law enforcement responded to. Law enforcement personnel do not respond to every overdose, and therefore, the numbers in this report are not representative of all overdoses in the state. The overdoses included are limited to those that are suspected to have been caused, at least in part, by opioids. Inclusion is based on law enforcement's perception and representation in Records Management Systems (RMS). All Vermont law enforcement agencies are represented, with the exception of Norwich Police Department, Hartford Police Department, and Windsor Police Department, due to RMS access. Questions regarding this dataset can be directed to the Vermont Intelligence Center at dps.vicdrugs@vermont.gov.Overdoses Indicators:The number of accidental and undetermined opioid-related deathsThe number of accidental and undetermined opioid-related deaths with cocaine involvementThe percent of accidental and undetermined opioid-related deaths with cocaine involvementThe rate of accidental and undetermined opioid-related deathsThe rate of heroin nonfatal overdose per 10,000 ED visitsThe rate of opioid nonfatal overdose per 10,000 ED visitsThe rate of stimulant nonfatal overdose per 10,000 ED visitsData Source:Vermont requires towns to report all births, marriages, and deaths. These records, particularly birth and death records are used to study and monitor the health of a population. Deaths are reported via the Electronic Death Registration System. Vermont publishes annual Vital Statistics reports.The Electronic Surveillance System for the Early Notification of Community-based Epidemics (ESSENCE) captures and analyzes recent Emergency Department visit data for trends and signals of abnormal activity that may indicate the occurrence of significant public health events.Population Health Indicators:The percent of adolescents in grades 6-8 who used marijuana in the past 30 daysThe percent of adolescents in grades 9-12 who used marijuana in the past 30 daysThe percent of adolescents in grades 9-12 who drank any alcohol in the past 30 daysThe percent of adolescents in grades 9-12 who binge drank in the past 30 daysThe percent of adolescents in grades 9-12 who misused any prescription medications in the past 30 daysThe percent of adults who consumed alcohol in the past 30 daysThe percent of adults who binge drank in the past 30 daysThe percent of adults who used marijuana in the past 30 daysData Sources:The Vermont Youth Risk Behavior Survey (YRBS) is part of a national school-based surveillance system conducted by the Centers for Disease Control and Prevention (CDC). The YRBS monitors health risk behaviors that contribute to the leading causes of death and disability among youth and young adults.The Behavioral Risk Factor Surveillance System (BRFSS) is a telephone survey conducted annually among adults 18 and older. The Vermont BRFSS is completed by the Vermont Department of Health in collaboration with the Centers for Disease Control and Prevention (CDC).Notes:Prevalence estimates and trends for the 2021 Vermont YRBS were likely impacted by significant factors unique to 2021, including the COVID-19 pandemic and the delay of the survey administration period resulting in a younger population completing the survey. Students who participated in the 2021 YRBS may have had a different educational and social experience compared to previous participants. Disruptions, including remote learning, lack of social interactions, and extracurricular activities, are likely reflected in the survey results. As a result, no trend data is included in the 2021 report and caution should be used when interpreting and comparing the 2021 results to other years.The Vermont Department of Health (VDH) seeks to promote destigmatizing and equitable language. While the VDH uses the term "cannabis" to reflect updated terminology, the data sources referenced in this data brief use the term "marijuana" to refer to cannabis. Prescription Drugs Indicators:The average daily MMEThe average day's supplyThe average day's supply for opioid analgesic prescriptionsThe number of prescriptionsThe percent of the population receiving at least one prescriptionThe percent of prescriptionsThe proportion of opioid analgesic prescriptionsThe rate of prescriptions per 100 residentsData Source:The Vermont Prescription Monitoring System (VPMS) is an electronic data system that collects information on Schedule II-IV controlled substance prescriptions dispensed by pharmacies. VPMS proactively safeguards public health and safety while supporting the appropriate use of controlled substances. The program helps healthcare providers improve patient care. VPMS data is also a health statistics tool that is used to monitor statewide trends in the dispensing of prescriptions.Treatment Indicators:The number of times a new substance use disorder is diagnosed (Medicaid recipients index events)The number of times substance use disorder treatment is started within 14 days of diagnosis (Medicaid recipients initiation events)The number of times two or more treatment services are provided within 34 days of starting treatment (Medicaid recipients engagement events)The percent of times substance use disorder treatment is started within 14 days of diagnosis (Medicaid recipients initiation rate)The percent of times two or more treatment services are provided within 34 days of starting treatment (Medicaid recipients engagement rate)The MOUD treatment rate per 10,000 peopleThe number of people who received MOUD treatmentData Source:Vermont Medicaid ClaimsThe Vermont Prescription Monitoring System (VPMS)Substance Abuse Treatment Information System (SATIS)
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
BackgroundPatients with opioid dependency prescribed opioid agonist treatment (OAT) may also be prescribed sedative drugs. This may increase mortality risk but may also increase treatment duration, with overall benefit. We hypothesised that prescription of benzodiazepines in patients receiving OAT would increase risk of mortality overall, irrespective of any increased treatment duration.Methods and findingsData on 12,118 patients aged 15â64 years prescribed OAT between 1998 and 2014 were extracted from the Clinical Practice Research Datalink. Data from the Office for National Statistics on whether patients had died and, if so, their cause of death were available for 7,016 of these patients. We identified episodes of prescription of benzodiazepines, z-drugs, and gabapentinoids and used linear regression and Cox proportional hazards models to assess the associations of co-prescription (prescribed during OAT and up to 12 months post-treatment) and concurrent prescription (prescribed during OAT) with treatment duration and mortality. We examined all-cause mortality (ACM), drug-related poisoning (DRP) mortality, and mortality not attributable to DRP (non-DRP). Models included potential confounding factors. In 36,126 person-years of follow-up there were 657 deaths and 29,540 OAT episodes, of which 42% involved benzodiazepine co-prescription and 29% concurrent prescription (for z-drugs these respective proportions were 20% and 11%, and for gabapentinoids 8% and 5%). Concurrent prescription of benzodiazepines was associated with increased duration of methadone treatment (adjusted mean duration of treatment episode 466 days [95% CI 450 to 483] compared to 286 days [95% CI 275 to 297]). Benzodiazepine co-prescription was associated with increased risk of DRP (adjusted HR 2.96 [95% CI 1.97 to 4.43], p
Facebook
TwitterOpen Government Licence - Canada 2.0https://open.canada.ca/en/open-government-licence-canada
License information was derived automatically
Data from surveillance reports provide information on opioid- and stimulant-related harms (deaths, hospitalizations, emergency department visits, and responses by emergency medical services) in Canada. The Public Health Agency of Canada (PHAC) works closely with the provinces and territories to collect and share accurate information about the overdose crisis in order to provide a national picture of the public health impact of opioids and other drugs in Canada and to help guide efforts to reduce substance-related harms.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Illicit Drug Use reports an estimated average percent of people who consumed illicit substances by type of use and by age range. Illicit drugs include marijuana or hashish (unless otherwise specified as 'Not Including Marijuana'), cocaine (including crack), heroin, hallucinogens (including phencyclidine [PCP], lysergic acid diethylamide [LSD], and Ecstasy [MDMA]), inhalants, or prescription-type psychotherapeutics used nonmedically, which include pain relievers, tranquilizers, stimulants, and sedatives, but does not include GHB (gamma hydroxybutyrate), Adderall, Ambien, nonprescription cough or cold medicines, ketamine, DMT (dimethyltryptamine), AMT (alpha-methyltryptamine), 5-MeO-DIPT (N, N-diisopropyl-5-methoxytryptamine, also known as 'Foxy'), and Salvia divinorum. Dependence is defined consistent with the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) definition as:Spending a lot of time engaging in activities related to substance useUsing a substance in greater quantities or for a longer time than intended. Developing tolerance (i.e., needing to use the substance more than before to get desired effects or noticing that the same amount of substance use had less effect than before)Making unsuccessful attempts to cut down on useContinuing substance use despite physical health or emotional problems associated with substance useReducing or eliminating participation in other activities because of substance useExperiencing withdrawal symptomsSimilarly, Abuse is also defined consistent with the DSM-IV definition as the following lifestyle symptoms due to the use of illicit drugs in the past 12 months: Experiencing problems at work, home, and schoolDoing something physically dangerousExperiencing Repeated trouble with the law
Facebook
Twitterhttps://creativecommons.org/publicdomain/zero/1.0/https://creativecommons.org/publicdomain/zero/1.0/
The following dataset is the World Drug Report 2021 produced by the United Nations Office on Drugs and Crime. https://www.unodc.org/unodc/en/data-and-analysis/wdr2021_annex.html
The Executive Summary: https://www.unodc.org/res/wdr2021/field/WDR21_Booklet_1.pdf
Special points of interest from the report: - Cannabis has come to be seen as less risky by adolescents from 1995 to 2019, but the herb potency has increased 4x in that time period. - Web-based sales have increased dramatically. - Number of drug users in Africa is projected to rise by 40 per cent by 2030, based on expected population growth in the 15-64 demographic. - Drug markets quickly recovered after the onset of the pandemic, but some trafficking dynamics have been accelerated during Covid-19 - Non-medical use of cannabis and sedatives has increased globally during the pandemic
On Opioids specifically: - The two pharmaceutical opioids most commonly used to treat people with opioid use disorders, methadone and buprenorphine, have become increasingly accessible over the past two decades. The amount available for medical use has increased sixfold since 1999, from 557 million daily doses in that year to 3,317 million by 2019. - The amounts of fentanyl and its analogues seized globally have risen rapidly in recent years, and by more than 60 per cent in 2019 compared with a year earlier. Overall, these amounts have risen more than twenty-fold since 2015. The largest quantities were seized in North America. - Elsewhere in the world, other pharmaceutical opioids (codeine and tramadol) predominate. Over the period 2015â2019, the largest quantities of tramadol seized were reported in West and Central Africa; they accounted for 86 per cent of the global total. Codeine was intercepted in large quantities in Asia, often in the form of diverted cough syrups. - Almost 50,000 people died from overdose deaths attributed to opioids in the United States in 2019, more than double the 2010 figure. By comparison, in the European Union, the figure for all drug-related overdoses (mostly relating to opioid use) stood at 8,300 in 2018, despite the larger population. - However, the opioid crisis in North America is evolving. The number of deaths attributed to heroin and the non-medical use of pharmaceutical opioids such as oxycodone or hydrocodone has been declining over the past five years. - The crisis is now driven mainly by overdose deaths attributed to synthetic opioids such as fentanyl and its analogues. Among the reasons for the large number of overdose deaths attributed to fentanyls is that the lethal doses of them are often small when compared with other opioids. Fentanyl is up to 100 times more potent than morphine. - The impact of fentanyl is illustrated even further by the fact that more than half of the deaths attributed to heroin also involve fentanyls. Synthetic opioids also contribute significantly to the increased number of overdose deaths attributed to cocaine and other psychostimulants, such as methamphetamine.
Facebook
TwitterThe Estonian Drug Treatment Database is a state register which is kept on the people who have started drug treatment. The Drug Treatment Database started its work on January 1, 2008.
Collection and processing of data on these people is necessary for getting an overview on occurrence of mental and behavioural disorders related to drug use, as well as for organising of relevant health services and planning of drug abuse preventive actions. Health care institutions holding a psychiatry authorization in Estonia present data to the database if they are turned to by a patient who is diagnosed with a mental and behavioural disorder due to drug use.
On the basis of the database's data, an annual overview is compiled, giving information about drug addicts who have turned to drug treatment in the previous calendar year, about the health service provided, the patients' socio-economic background, drug use and the related risk behaviour.
The data on the Drug Treatment Database are also submitted to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and United Nations Office on Drugs and Crime (UNODC).
Facebook
TwitterEinstellung zu Drogen. Themen: PrĂ€ferierte Ansprechpartner fĂŒr Informationen ĂŒber illegale Drogen und Drogenkonsum; Informationsquellen fĂŒr Informationen zu Auswirkungen und Risiken des Drogenkonsums; Konsum ÂŽneuer psychoaktiver Substanzen (NPS)ÂŽ (ÂŽLegal HighsÂŽ), die die Wirkung illegaler Drogen imitieren, in den letzten zwölf Monaten; Kauf der neuen synthetischen Drogen von einem Freund, in einem SpezialgeschĂ€ft, im Internet bzw. von einem Drogendealer; Konsumsituation (allein, mit Freunden, wĂ€hrend einer Party oder Veranstaltung bzw. im Alltag); Informationsquellen fĂŒr erhaltene Informationen zu Auswirkungen und Risiken des Konsums neuer synthetischer Drogen; EinschĂ€tzung des Gesundheitsrisikos jeweils beim ein- oder zweimaligen Konsum und beim regelmĂ€Ăigen Konsum von Cannabis, Ecstasy, Alkohol, Kokain sowie von neuen synthetischen Drogen, die die Wirkung illegaler Drogen imitieren; effektivste staatliche MaĂnahmen zur Reduzierung der Drogenproblematik (Kampagnen zur Information und Vorbeugung, Behandlung und Rehabilitation von Drogenkonsumenten, strenge MaĂnahmen gegen Drogendealer und DrogenhĂ€ndler bzw. gegen Drogenkonsumenten, Drogen legalisieren, Reduzierung von Armut und Arbeitslosigkeit mehr Freizeitangebote fĂŒr Jugendliche); Forderung nach einem (weiteren) Verbot oder einer gesetzlichen Regelung des Konsums ausgewĂ€hlter Substanzen (Cannabis, Tabak, Ecstasy, Heroin, Alkohol, Kokain); geeigneter Umgang mit legalen neuen psychoaktiven Substanzen (Regulierung einfĂŒhren, Verbot nur bei Gesundheitsrisiko, generelles Verbot, nichts tun); Beschaffungsmöglichkeit ausgewĂ€hlter Substanzen innerhalb von 24 Stunden (Cannabis, Alkohol, Kokain, Ecstasy, Tabak, Heroin, neue psychoaktive Substanzen); Cannabiskonsum. Demographie: Alter; Geschlecht; höchster Bildungsabschluss; BeschĂ€ftigungsstatus und berufliche Stellung des Haupteinkommensbeziehers im Haushalt (falls Befragter SchĂŒler oder Student); BeschĂ€ftigungsstatus und berufliche Stellung des Befragten; Region; Urbanisierungsgrad des Wohnortes; Mobiltelefonbesitz; Festnetztelefon im Haushalt; Anzahl der Personen im Haushalt ab 15 Jahren (HaushaltsgröĂe). Attitude towards drugs. Topics: Preferred contact for information about illicit drugs and drug use in general; information sources for information about the effects and risks of drug use of illicit drugs; consumption of new psychoactive substances (âlegal highsâ) that imitate the effects of illicit drugs, in the last year; purchase of new substances by a friend, from a specialised shop, from the Internet or from a drug dealer; circumstances of use (alone, with friends, during a party or an event or during normal daily activities); information sources for information about the effects and risks of the use of new substances; assessment of the risk to a personâs health using cannabis, ecstasy, alcohol, cocaine, and new substances that imitate the effects of illicit drugs, once or twice and regularly; most effective ways for public authorities to reduce drugs problems (information and prevention campaigns, treatment and rehabilitation of drug users, tough measures against drug dealers and traffickers, as well as drug users, legalize drugs, reduction of poverty and unemployment, more leisure activities for young people); demand for (continued) banning or a legal regulation of the following substances (cannabis, tobacco, ecstasy, heroin, alcohol, cocaine); appropriate way to handle new psychoactive substances (introduce regulation, ban them only if they pose a risk to health, ban them under any circumstance, do nothing); possibility to obtain selected substances within 24 hours (cannabis, alcohol, cocaine, ecstasy, tobacco, heroin, new psychoactive substances); respondent has used cannabis. Demography: age; sex; highest education level; occupation and professional position of the main wage earner in the household (only full time students); occupation and professional position of the respondent; region; type of community; own a mobile phone and fixed (landline) phone in the household; number of persons aged 15 years and older in the household (household size). Telephone interview: CATI Bevölkerung der jeweiligen NationalitĂ€ten der 28 Mitgliedsstaaten der EU, wohnhaft in den jeweiligen Mitgliedsstaaten im Alter zwischen 15 und 24 Jahren Die Umfrage umfast die nationale Bevölkerung der BĂŒrger (in diesen LĂ€ndern) sowie die Bevölkerung der BĂŒrger aller Mitgliedstaaten der EuropĂ€ischen Union, die Bewohner dieser LĂ€nder sind und ĂŒber ausreichende Kenntnisse der Landessprachen verfĂŒgen, um den Fragebogen zu beantworten. Population of the respective nationalities of the European Union Member States, resident in each of the 28 Member States and aged between 15 and 24 years old. The survey covers the national population of citizens (in these countries) as well as the population of citizens of all the European Union Member States that are residents in these countries and have a sufficient command of the national languages to answer the questionnaire.
Facebook
Twitterhttps://creativecommons.org/publicdomain/zero/1.0/https://creativecommons.org/publicdomain/zero/1.0/
This directory contains data behind the story How Baby Boomers Get High. It covers 13 drugs across 17 age groups.
Source: National Survey on Drug Use and Health from the Substance Abuse and Mental Health Data Archive.
| Header | Definition |
|---|---|
alcohol-use | Percentage of those in an age group who used alcohol in the past 12 months |
alcohol-frequency | Median number of times a user in an age group used alcohol in the past 12 months |
marijuana-use | Percentage of those in an age group who used marijuana in the past 12 months |
marijuana-frequency | Median number of times a user in an age group used marijuana in the past 12 months |
cocaine-use | Percentage of those in an age group who used cocaine in the past 12 months |
cocaine-frequency | Median number of times a user in an age group used cocaine in the past 12 months |
crack-use | Percentage of those in an age group who used crack in the past 12 months |
crack-frequency | Median number of times a user in an age group used crack in the past 12 months |
heroin-use | Percentage of those in an age group who used heroin in the past 12 months |
heroin-frequency | Median number of times a user in an age group used heroin in the past 12 months |
hallucinogen-use | Percentage of those in an age group who used hallucinogens in the past 12 months |
hallucinogen-frequency | Median number of times a user in an age group used hallucinogens in the past 12 months |
inhalant-use | Percentage of those in an age group who used inhalants in the past 12 months |
inhalant-frequency | Median number of times a user in an age group used inhalants in the past 12 months |
pain-releiver-use | Percentage of those in an age group who used pain relievers in the past 12 months |
pain-releiver-frequency | Median number of times a user in an age group used pain relievers in the past 12 months |
oxycontin-use | Percentage of those in an age group who used oxycontin in the past 12 months |
oxycontin-frequency | Median number of times a user in an age group used oxycontin in the past 12 months |
tranquilizer-use | Percentage of those in an age group who used tranquilizer in the past 12 months |
tranquilizer-frequency | Median number of times a user in an age group used tranquilizer in the past 12 months |
stimulant-use | Percentage of those in an age group who used stimulants in the past 12 months |
stimulant-frequency | Median number of times a user in an age group used stimulants in the past 12 months |
meth-use | Percentage of those in an age group who used meth in the past 12 months |
meth-frequency | Median number of times a user in an age group used meth in the past 12 months |
sedative-use | Percentage of those in an age group who used sedatives in the past 12 months |
sedative-frequency | Median number of times a user in an age group used sedatives in the past 12 months |
This is a dataset from FiveThirtyEight hosted on their GitHub. Explore FiveThirtyEight data using Kaggle and all of the data sources available through the FiveThirtyEight organization page!
This dataset is maintained using GitHub's API and Kaggle's API.
This dataset is distributed under the Attribution 4.0 International (CC BY 4.0) license.
Cover photo by Eric Muhr on Unsplash
Unsplash Images are distributed under a unique Unsplash License.
Facebook
TwitterOpioid addiction and death rates in the U.S. and abroad have reached "epidemic" levels. The CDC's data reflects the incredible spike in overdoses caused by drugs containing opioids.
The United States is experiencing an epidemic of drug overdose (poisoning) deaths. Since 2000, the rate of deaths from drug overdoses has increased 137%, including a 200% increase in the rate of overdose deaths involving opioids (opioid pain relievers and heroin). Source: CDC
Retrieved from https://data.world/health/opioid-overdose-deaths Image by Dan Meyers on Unsplash
Citation for Opioid Prescription Data: IMS Health, Vector One: National, years 1991-1996, Data Extracted 2011. IMS Health, National Prescription Audit, years 1997-2013, Data Extracted 2014. Accessed at NIDA article linked (Figure 1) on Oct 23, 2016.
Data Use Restrictions: The Public Health Service Act (42 U.S.C. 242m(d)) provides that the data collected by the National Center for Health Statistics (NCHS) may be used only for the purpose for which they were obtained; any effort to determine the identity of any reported cases, or to use the information for any purpose other than for health statistical reporting and analysis, is against the law. Therefore users will: Use these data for health statistical reporting and analysis only. For sub-national geography, do not present or publish death counts of 9 or fewer or death rates based on counts of nine or fewer (in figures, graphs, maps, tables, etc.). Make no attempt to learn the identity of any person or establishment included in these data. Make no disclosure or other use of the identity of any person or establishment discovered inadvertently and advise the NCHS Confidentiality Officer of any such discovery. Eve Powell-Griner, Confidentiality Officer National Center for Health Statistics 3311 Toledo Road, Rm 7116 Hyattsville, MD 20782 Telephone 301-458-4257 Fax 301-458-4021
Your data will be in front of the world's largest data science community. What questions do you want to see answered?
Facebook
TwitterData on drug overdose death rates, by drug type and selected population characteristics. Please refer to the PDF or Excel version of this table in the HUS 2019 Data Finder (https://www.cdc.gov/nchs/hus/contents2019.htm) for critical information about measures, definitions, and changes over time. SOURCE: NCHS, National Vital Statistics System, numerator data from annual public-use Mortality Files; denominator data from U.S. Census Bureau national population estimates; and Murphy SL, Xu JQ, Kochanek KD, Arias E, Tejada-Vera B. Deaths: Final data for 2018. National Vital Statistics Reports; vol 69 no 13. Hyattsville, MD: National Center for Health Statistics.2021. Available from: https://www.cdc.gov/nchs/products/nvsr.htm. For more information on the National Vital Statistics System, see the corresponding Appendix entry at https://www.cdc.gov/nchs/data/hus/hus19-appendix-508.pdf.